Posted by Michael Wonder on 15 Nov 2016
NICE says pancreatic cancer treatment considered not cost effective for routine NHS use
15 November 2016 - The drug pegylated liposomal irinotecan, was not clinically effective enough to justify its high cost, NICE says in draft guidance.
The NICE appraisal committee, looked at research showing patients taking the drug lived on average two months longer than those receiving usual care, and said it did not offer value for money for widespread NHS use.
The committee realised that any treatment that could offer a longer and better life was extremely important to people with this condition. They also appreciated that there have been few new treatments in this area.
